MIRM

Mirum Pharmaceuticals, Inc. [MIRM] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

MIRM Stock Summary

Top 10 Correlated ETFs

MIRM

Top 10 Correlated Stocks

MIRM

In the News

MIRM Financial details

Company Rating
-
Market Cap
1.15B
Income
-160.91M
Revenue
186.37M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
264
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-6.99
Forward P/E
-
PEG
-280.3
P/S
8.99
P/B
4.26
P/C
-
P/FCF
-15.18
Quick Ratio
4.74
Current Ratio
5.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.02
EPS next Y
-
EPS next Q
-
EPS this Y
-0.25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
45.74%
EPS Q/Q
24.56%
-
-
-
-
SMA20
10.85%
SMA50
13.47%
SMA100
31.83%
Inst Own
-
Inst Trans
-
ROA
-25%
ROE
137%
ROC
-0.19%
Gross Margin
82%
Oper. Margin
-77%
Profit Margin
-113%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
24.23-35.56
52W High
+49.86%
52W Low
+118.54%
RSI
64.07
Rel Volume
1.67
Avg Volume
543.31K
Volume
905.22K
Perf Week
4.57%
Perf Month
24.7%
Perf Quarter
19.56%
Perf Half Y
27.18%
-
-
-
-
Beta
1.136
-
-
Volatility
1.11%, 3.04%
Prev Close
-1.34%
Price
52.45
Change
0.54%

Something similar

Top by Market Cap
MIX.JO
VFINX
META
0YXG.L
LLY.DE
Top Correlated ETFs
RPAR
QQXT
VFMV
UPAR
IDV
Top Correlated Stocks
VIGL
GSK
KALV
LQDA
NWG
Similar Market Cap
ZV.MI
1689.HK
TINLY
PRK
ORA.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 543.31K
  • Market Capitalization 1.15B
  • Employee 264
  • CEO Mr. Christopher Peetz
  • Headquarters Foster City,CA,US
  • IPO Date 2019-07-18
  • Website https://www.mirumpharma.com

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.